BAKER BROS. ADVISORS LP's Net Worth

$40.1 Million

Who is BAKER BROS. ADVISORS LP?

BAKER BROS. ADVISORS LP has an estimated net worth of $40.1 Million. This is based on reported shares across multiple companies, which include Seagen Inc., RHYTHM PHARMACEUTICALS, INC., BeiGene, Ltd., INCYTE CORP, Invitae Corp, Prelude Therapeutics Inc, XOMA Corp, Kiniksa Pharmaceuticals, Ltd., Mirati Therapeutics, Inc., Zymeworks Inc., Intellia Therapeutics, Inc., Entrada Therapeutics, Inc., IGM Biosciences, Inc., Kodiak Sciences Inc., ACADIA PHARMACEUTICALS INC, BIOCRYST PHARMACEUTICALS INC, IDERA PHARMACEUTICALS, INC., DBV Technologies S.A., TScan Therapeutics, Inc., Neurogene Inc., Atreca, Inc., Aeglea BioTherapeutics, Inc., BELLICUM PHARMACEUTICALS, INC, HOOKIPA Pharma Inc., Talis Biomedical Corp, ALEXION PHARMACEUTICALS INC, MADRIGAL PHARMACEUTICALS, INC., SYNAGEVA BIOPHARMA CORP, GENOMIC HEALTH INC, Principia Biopharma Inc., Ardea Biosciences, Inc./DE, vTv Therapeutics Inc., Kymera Therapeutics, Inc., BICYCLE THERAPEUTICS PLC, Immunocore Holdings plc, and KALA BIO, Inc..

SEC CIK

BAKER BROS. ADVISORS LP's CIK is 0001263508

Past Insider Trading and Trends

2019 was BAKER BROS. ADVISORS LP's most active year for acquiring shares with 14 total transactions. BAKER BROS. ADVISORS LP's most active month to acquire stocks was the month of May. 2023 was BAKER BROS. ADVISORS LP's most active year for disposing of shares, totalling 4 transactions. BAKER BROS. ADVISORS LP's most active month to dispose stocks was the month of February. 2016 saw BAKER BROS. ADVISORS LP paying a total of $1,846.76 for 274 shares, this is the most they've acquired in one year. In 2023 BAKER BROS. ADVISORS LP cashed out on 464,907 shares for a total of $10,661,553.00, their largest year based on trade value.